Last Updated: November 20, 2026

Details for Patent: 4,895,726

« Back to Dashboard


Summary for Patent: 4,895,726
Title:Novel dosage form of fenofibrate
Abstract:The present invention relates to a novel dosage form of fenofibrate containing fenofibrate and a solid surfactant which have been co-micronized. It also relates to the method for the preparation of this dosage form and its use for improving the bioavailabity in vivo.
Inventor(s):Bernard Curtet, Eric Teillaud, Philippe Reginault
Assignee: Fournier Industrie et Sante SAS
Application Number:US07/299,073
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;
Patent landscape, scope, and claims:

United States Patent 4,895,726: Fenofibrate Micronization Claims, Scope, Expiration, and Patent Landscape

U.S. Patent 4,895,726 protected a specific fenofibrate formulation technology: co-micronization of fenofibrate with a solid surfactant, principally sodium lauryl sulfate, to produce particles below 15 micrometers and improve oral bioavailability. The patent also covered a manufacturing process, gelatin-capsule dosage forms, and treatment of hyperlipidemia and hypercholesterolemia.

The patent issued on January 23, 1990, and expired on January 23, 2007, under the pre-1995 patent term rule of 17 years from issuance. It no longer creates an enforceable patent barrier to generic fenofibrate products.[1] Its historical commercial importance was substantial because it supported micronized 200-mg fenofibrate capsules associated with the original Tricor and related fenofibrate products.

What invention does U.S. Patent 4,895,726 protect?

The patent protects a formulation in which fenofibrate is not merely micronized alone. The claimed active ingredient is co-micronized with a solid surfactant before the remaining excipients are incorporated.

The core technical concept has four elements:

  1. Fenofibrate particles are combined with a solid surfactant.
  2. The mixture is co-micronized rather than separately micronized and blended.
  3. The resulting mean particle size is below 15 micrometers.
  4. The powder is formulated into a gelatin capsule for oral treatment.

The disclosed purpose is improved dissolution and bioavailability of fenofibrate, a poorly water-soluble lipid-lowering compound. Sodium lauryl sulfate functions as the principal surfactant identified in the claims.

The patent therefore targets a formulation and manufacturing platform, not the fenofibrate molecule itself. Fenofibrate was known before the patent and could not be monopolized by this patent as a chemical compound.

What are the independent claims of Patent 4,895,726?

The patent contains four principal claim categories.

Claim Claim category Main limitation
1 Therapeutic composition Gelatin capsule containing co-micronized fenofibrate and solid surfactant with mean particle size below 15 µm
8 Manufacturing method Co-micronization, wet granulation, drying, grading, excipient addition, and capsule filling
10 Bioavailability method Co-micronization of fenofibrate and solid surfactant until particle size is below 15 µm
11 Treatment method Oral administration of the composition of claim 6 for hyperlipidemia or hypercholesterolemia

Claims 2 through 7 narrow claim 1. Claims 9, 12 and related dependent claims narrow the manufacturing, bioavailability, or treatment claims.

The strongest commercial claim was claim 1 because it captures a finished dosage form. Claim 8 is narrower but potentially relevant to manufacturing operations. Claim 10 focuses on the process used to improve in-vivo bioavailability. Claims 11 and 12 cover treatment with the more specific sodium-lauryl-sulfate formulation and particle-size limits.

How should claim 1 be construed?

Claim 1 requires more than a capsule containing micronized fenofibrate. Its principal limitations are cumulative.

Gelatin capsule

The product must be presented in gelatin capsules. A tablet, liquid suspension, softgel, or other dosage form would not literally satisfy this limitation unless another claim-construction theory applied.

The gelatin-capsule limitation was commercially relevant to early fenofibrate products but reduced the claim's reach against later tablet and reformulated products.

Co-micronized mixture

"Co-micronized" is the central technical limitation. The claim requires fenofibrate and the solid surfactant to be intimately mixed and micronized together.

A product made by:

  • micronizing fenofibrate alone,
  • separately processing the surfactant, and
  • blending the two powders afterward

would present a non-infringement argument because it would lack the claimed co-micronization step or structure.

The distinction between co-micronization and post-micronization blending would be important in both infringement analysis and process discovery.

Mean particle size below 15 micrometers

The claim uses mean particle size, not a maximum particle size. A product could contain particles above 15 micrometers and still potentially fall within the claim if the measured mean remained below the threshold.

Particle-size methodology would therefore matter. Relevant variables include:

  • laser diffraction versus microscopy;
  • dry-powder versus dispersed measurement;
  • treatment of agglomerates;
  • number-weighted versus volume-weighted mean;
  • sampling location and batch variability.

Claims 6 and 12 add tighter thresholds of 10 micrometers and 5 micrometers, respectively.

Solid surfactant

The surfactant must be solid under the relevant formulation conditions. Claim 4 specifically narrows the composition to sodium lauryl sulfate, also known as sodium dodecyl sulfate.

The broadest version of claim 1 is not limited to sodium lauryl sulfate, but the solid surfactant must remain within the claim's formulation and co-micronization architecture.

What do the dependent claims add?

Claim Added limitation Commercial or legal effect
2 Surfactant-to-fenofibrate weight ratio of approximately 0.75/100 to 10.5/100 Narrows the formulation to a defined surfactant loading range
3 200 mg fenofibrate per therapeutic unit Targets the original 200-mg capsule presentation
4 Sodium lauryl sulfate as solid surfactant Narrows the surfactant identity
5 Sodium lauryl sulfate at 0.5% to 7% of total formulation weight Adds total-formulation concentration limits
6 Mean particle size of 10 µm or less and sodium lauryl sulfate Creates a tighter formulation claim
7 Dispersants, fillers and flow enhancers Incorporates conventional excipient classes
9 Co-micronized fenofibrate and sodium lauryl sulfate below 15 µm Narrows the manufacturing process
12 Particle size of 5 µm or less Creates the narrowest treatment-method limitation

Claim 3 is especially relevant to the original product configuration. A later product containing 145 mg or 160 mg fenofibrate would not literally satisfy the 200-mg limitation in claim 3, although it could still implicate broader claims if the other limitations were met.

What manufacturing process does claim 8 protect?

Claim 8 requires a defined sequence:

  1. Intimately mix fenofibrate and solid surfactant.
  2. Co-micronize the mixture.
  3. Add lactose and starch.
  4. Granulate with water.
  5. Dry to no more than 1% water.
  6. Grade the granules.
  7. Add polyvinylpyrrolidone and magnesium stearate.
  8. Fill gelatin capsules.

This is a process claim with multiple ordered steps. Literal infringement would generally require performance of each claimed step, including the specific excipients and drying endpoint.

The claim is narrower than claim 1 because a manufacturer could potentially avoid it by using:

  • a different granulation process;
  • a different filler or disintegrant;
  • dry granulation;
  • direct compression;
  • a different lubricant;
  • a different residual-moisture specification; or
  • a tablet rather than a gelatin capsule.

The process claim would have been difficult to enforce against a finished product without access to manufacturing records, batch instructions, or process validation documents.

Does Patent 4,895,726 cover fenofibrate itself?

No. The patent does not claim fenofibrate as a chemical entity. It covers particular pharmaceutical compositions and processes using fenofibrate.

This distinction affects freedom to operate:

  • fenofibrate as an active ingredient is not protected by this patent;
  • unmicronized fenofibrate is outside the central formulation concept;
  • micronized fenofibrate without co-micronized solid surfactant raises a different infringement question;
  • later fenofibrate formulations may have been subject to separate patents;
  • the expired patent cannot block current manufacture or sale.

When did U.S. Patent 4,895,726 expire?

Event Date
U.S. filing 1987
U.S. patent issuance January 23, 1990
Applicable term rule 17 years from issuance for pre-June 8, 1995 applications
Expiration January 23, 2007
Current enforceability Expired

The expiration date follows the patent term framework applicable when the application was filed. It is not calculated under the 20-year-from-earliest-effective-filing-date rule that applies to most later U.S. applications.[1][2]

Any regulatory exclusivity associated with a fenofibrate product would have been separate from this patent term. FDA marketing exclusivity does not revive an expired patent.

What was the Orange Book status of Patent 4,895,726?

Patent 4,895,726 was historically associated with the original fenofibrate capsule product and was listed in the FDA Orange Book for an approved fenofibrate product. Its listing had commercial significance during the period when generic applicants evaluated abbreviated new drug application, or ANDA, certification requirements.[3]

The patent is now expired and does not create a current Orange Book patent barrier. A historical Orange Book listing should not be interpreted as evidence that the patent remains enforceable.

For current regulatory analysis, the relevant questions are:

  • whether a particular fenofibrate reference product has active listed patents;
  • whether those patents cover the applicant's dosage form or formulation;
  • whether the product is approved through the ANDA pathway;
  • whether an applicant filed a Paragraph IV certification; and
  • whether any 30-month stay or litigation remains relevant.

Because fenofibrate is a small-molecule drug, biosimilar analysis does not apply. Generic applicants use the ANDA framework, not the biosimilar pathway under the Public Health Service Act.

Were there Paragraph IV challenges to the fenofibrate patent estate?

Fenofibrate generic competition involved ANDA litigation and Paragraph IV certifications directed at patents covering Tricor and later fenofibrate formulations. The competitive disputes did not depend solely on Patent 4,895,726. Later fenofibrate products used different strengths, dosage forms, particle technologies, and formulation approaches.

The legal significance of a Paragraph IV certification is product-specific. An ANDA applicant could assert that:

  • the listed patent was invalid;
  • the patent was unenforceable;
  • the proposed product would not infringe; or
  • the patent claims did not cover the proposed dosage form.

Patent 4,895,726 is no longer a practical Paragraph IV obstacle because its term ended in 2007. Later patents had to be assessed separately for products such as 48-mg, 145-mg, 160-mg, and 200-mg fenofibrate presentations.

What later patents affected fenofibrate products?

The fenofibrate patent estate developed through separate formulation and dosage-form patents after the original micronized-capsule patent. Representative U.S. patents associated with later fenofibrate products include the following:

Patent General subject matter Relevance
U.S. 4,895,726 Co-micronized fenofibrate and solid surfactant in gelatin capsules Foundational micronized-capsule technology; expired
U.S. 5,880,148 Fenofibrate pharmaceutical composition technology Later formulation protection
U.S. 6,074,670 Fenofibrate composition and delivery technology Associated with later commercial formulations
U.S. 6,277,405 Fenofibrate pharmaceutical composition Relevant to later dosage forms and generic disputes
U.S. 6,589,552 Fenofibrate formulation technology Later-generation formulation protection

The exact scope and expiration of each later patent must be evaluated against its claims, prosecution history, term adjustments, terminal disclaimers, and Orange Book listing. A generic product that avoids Patent 4,895,726 may still encounter a later formulation patent.

The main commercial transition was from the original 200-mg micronized capsule to lower-dose and reformulated products, including 48-mg and 145-mg presentations. Reformulation allowed sponsors to pursue improved dissolution, dose flexibility, and product differentiation while creating new patent positions.

How strong was the patent estate for the original product?

The original patent had moderate-to-strong protection for the specific product architecture but limited scope outside it.

Strengths

  • It claimed the combination of micronized fenofibrate and solid surfactant.
  • It captured a defined particle-size threshold.
  • It included product, process, bioavailability, and treatment claims.
  • It aligned closely with the commercial 200-mg gelatin-capsule product.
  • It covered co-micronization, a manufacturing feature not necessarily visible from the finished dosage form.

Limitations

  • It did not claim fenofibrate itself.
  • It required a gelatin capsule.
  • It depended on the co-micronization concept.
  • Several claims required sodium lauryl sulfate.
  • Claims 3 and 5 imposed specific dose or concentration limits.
  • The patent expired in 2007.
  • Later tablet and reformulated products could be designed around several limitations.

Its historical blocking power was therefore strongest against generic versions of the same 200-mg micronized capsule and weakest against materially different dosage forms or processes.

What generic launch risks existed?

Before expiration, a generic applicant would have faced four principal risks.

Product-composition risk

A proposed capsule containing co-micronized fenofibrate and a solid surfactant below the claimed particle size could have presented direct infringement risk under claim 1.

Process risk

A manufacturer using the claimed lactose-starch wet-granulation sequence could have faced process-claim risk under claim 8, even if the finished product's composition was difficult to characterize.

Measurement risk

A particle-size result below 15 micrometers could support infringement, but the parties would likely dispute analytical methods and batch representativeness.

Regulatory-patent risk

An ANDA applicant would have needed to address any listed patent for the reference product through a Paragraph I, II, III, or IV certification. That regulatory issue was separate from the scientific question of whether the product used the claimed formulation.

Today, Patent 4,895,726 creates no launch risk because it is expired. Current risk depends on active later patents, regulatory exclusivity, manufacturing know-how, and product-specific Orange Book records.

Are there biosimilar risks or manufacturing barriers?

There is no biosimilar risk because fenofibrate is a chemically synthesized small molecule. The relevant competition is generic fenofibrate under the ANDA pathway.

Manufacturing barriers are lower than patent barriers now. The process requires conventional pharmaceutical operations:

  • powder mixing;
  • micronization;
  • wet granulation;
  • drying;
  • grading;
  • lubricant blending; and
  • capsule filling.

The more difficult technical issues are process reproducibility, particle-size control, dissolution performance, surfactant distribution, and stability. Those issues can affect FDA approval without creating an enforceable monopoly under the expired patent.

What licensing deals affected the patent?

Laboratoires Fournier was the original patent owner and developer associated with the technology. Fournier's fenofibrate business later became connected with Abbott Laboratories through commercial and corporate transactions involving Tricor and related products.

The patent record does not establish a continuing license restriction that survives expiration. Any historical license, assignment, or collaboration involving the patent cannot extend the patent's statutory term.

What is the current competitive landscape?

The fenofibrate market includes generic products in multiple strengths and dosage forms. Competitive differentiation has centered on:

  • micronized versus non-micronized material;
  • capsule versus tablet dosage forms;
  • 48-mg, 145-mg, 160-mg and 200-mg strengths;
  • fed-state and food-effect performance;
  • dissolution and bioavailability;
  • combination therapy with statins; and
  • manufacturing cost.

The original 200-mg capsule technology remains important as a historical reference point, but current market access is governed by generic approvals and any surviving later formulation patents rather than Patent 4,895,726.

Key Takeaways

  • U.S. Patent 4,895,726 covered co-micronized fenofibrate and a solid surfactant, particularly sodium lauryl sulfate.
  • The central particle-size threshold was a mean size below 15 micrometers.
  • The patent covered gelatin-capsule compositions, a defined manufacturing sequence, bioavailability improvement, and treatment methods.
  • Claims 6 and 12 narrowed the particle-size threshold to 10 micrometers and 5 micrometers.
  • The patent issued on January 23, 1990, and expired on January 23, 2007.
  • It no longer blocks generic fenofibrate products.
  • The patent did not claim fenofibrate as a chemical compound.
  • Later fenofibrate products relied on separate formulation and dosage-form patents.
  • Fenofibrate competition uses the ANDA pathway, not the biosimilar pathway.
  • Current freedom-to-operate analysis must focus on later patents, current Orange Book listings, formulation design, and manufacturing practices.

FAQs

Does Patent 4,895,726 cover all micronized fenofibrate products?

No. It targets co-micronized fenofibrate and solid surfactant in the claimed particle-size range, with additional dosage-form and formulation limitations. It does not claim all micronized fenofibrate.

Can a tablet infringe Patent 4,895,726?

A tablet would have a strong non-infringement position against claims requiring a gelatin capsule. It could still raise separate issues under a different patent estate, particularly patents directed to later tablet formulations.

Is sodium lauryl sulfate required by every claim?

No. Claim 1 broadly recites a solid surfactant. Claims 4, 5, 6 and 9 specifically narrow the invention to sodium lauryl sulfate.

Does a 145-mg fenofibrate product fall within claim 3?

No, not literally. Claim 3 requires 200 mg of fenofibrate per therapeutic unit. A 145-mg product could still require analysis under broader claims or later patents.

What patent protects generic fenofibrate today?

Patent 4,895,726 protects none because it expired in 2007. Any current patent issue must be evaluated against the specific fenofibrate product, dosage form, formulation, Orange Book listing, and active later patents.

References

  1. United States Patent and Trademark Office. (1990). U.S. Patent No. 4,895,726: Therapeutic composition based on fenofibrate and process for its preparation. https://patents.google.com/patent/US4895726
  2. United States Code. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title35-section154
  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  4. United States Patent and Trademark Office. (1999). U.S. Patent No. 5,880,148: Fenofibrate pharmaceutical compositions. https://patents.google.com/patent/US5880148
  5. United States Patent and Trademark Office. (2000). U.S. Patent No. 6,074,670: Fenofibrate pharmaceutical composition. https://patents.google.com/patent/US6074670
  6. United States Patent and Trademark Office. (2001). U.S. Patent No. 6,277,405: Fenofibrate pharmaceutical composition. https://patents.google.com/patent/US6277405
  7. United States Patent and Trademark Office. (2003). U.S. Patent No. 6,589,552: Fenofibrate pharmaceutical compositions. https://patents.google.com/patent/US6589552

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 4,895,726

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 4,895,726

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France88 02359Feb 26, 1988

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.